Gene · 10643
Papers3,038
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
361 to 380 of 3,038
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| METTL3-mediated m6A methylation of SLC38A1 stimulates cervical cancer growth. | Biochem Biophys Res Commun | 2024 | 38701556 | PubTator, text mining | PubMed |
| LARP4B promotes hepatocellular carcinoma progression and impairs sorafenib efficacy by activating SPINK1-mediated EGFR pathway. | Cell Death Discov | 2024 | 38693111 | PubTator, text mining | PubMed |
| Circ_0053943 complexed with IGF2BP3 drives uveal melanoma progression via regulating N6-methyladenosine modification of Epidermal growth factor receptor. | Oncol Res | 2024 | 38686044 | PubTator, text mining | PubMed |
| N6-methyladenosine methylation on FSCN1 mediated by METTL14/IGF2BP3 contributes to human papillomavirus type 16-infected cervical squamous cell carcinoma. | Clin Exp Pharmacol Physiol | 2024 | 38679464 | PubTator, text mining | PubMed |
| Effects and mechanisms of N6-methyladenosine RNA methylation in environmental pollutant-induced carcinogenesis. | Ecotoxicol Environ Saf | 2024 | 38669875 | PubTator, text mining | PubMed |
| Expression patterns of m6A RNA methylation regulators under apoptotic conditions in various human cancer cell lines. | Turk J Biol | 2024 | 38665783 | PubTator, text mining | PubMed |
| [Prognostic Value of IGF2BP3 Gene Expression Levels in Patients with Acute Myeloid Leukemia]. | Zhongguo Shi Yan Xue Ye Xue Za Zhi | 2024 | 38660836 | PubTator, text mining | PubMed |
| N6-methyladenosine-modified circTEAD1 stabilizes Yap1 mRNA to promote chordoma tumorigenesis. | Clin Transl Med | 2024 | 38659080 | PubTator, text mining | PubMed |
| N6-Methyladenosine-Modified KREMEN2 Promotes Tumorigenesis and Malignant Progression of High-Grade Serous Ovarian Cancer. | Lab Invest | 2024 | 38615731 | PubTator, text mining | PubMed |
| Targeting high circDNA2v levels in colorectal cancer induces cellular senescence and elicits an anti-tumor secretome. | Cell Rep | 2024 | 38615319 | PubTator, text mining | PubMed |
| Comprehensive analysis of IGF2BP3 with expression features, prognosis, immune modulation and stemness in hepatocellular carcinoma and pan-cancer. | J Cancer | 2024 | 38577615 | PubTator, text mining | PubMed |
| m6A-dependent upregulation of DDX21 by super-enhancer-driven IGF2BP2 and IGF2BP3 facilitates progression of acute myeloid leukaemia. | Clin Transl Med | 2024 | 38572589 | PubTator, text mining | PubMed |
| LIN28B induced PCAT5 promotes endometrial cancer progression and glycolysis via IGF2BP3 deubiquitination. | Cell Death Dis | 2024 | 38565547 | PubTator, text mining | PubMed |
| Hsa_circ_0005320 affects cell proliferation and the cell cycle via the IGF2BP3/CDK2 axis in bladder cancer. | Cell Signal | 2024 | 38565412 | PubTator, text mining | PubMed |
| Differential expression and clinical significance of IGF2BP3 in peritoneal dialysate of patients with varying duration of peritoneal dialysis. | Clin Transl Sci | 2024 | 38561910 | PubTator, text mining | PubMed |
| Systematic analysis of RNA-binding proteins identifies targetable therapeutic vulnerabilities in osteosarcoma. | Nat Commun | 2024 | 38561347 | PubTator, text mining | PubMed |
| Targeting MicroRNAs with Small Molecules. | Noncoding RNA | 2024 | 38525736 | PubTator, text mining | PubMed |
| IGF2BP3 prevent HMGB1 mRNA decay in bladder cancer and development. | Cell Mol Biol Lett | 2024 | 38504159 | PubTator, text mining | PubMed |
| Insights into the role of the N6-methyladenosine reader IGF2BP3 in the progression of oral squamous cell carcinoma and its connection to cell-cycle control. | Transl Oncol | 2024 | 38492500 | PubTator, text mining | PubMed |
| IGF2BP3 stabilizes SESN1 mRNA to mitigate oxidized low-density lipoprotein-induced oxidative stress and endothelial dysfunction in human umbilical vein endothelial cells by activating Nrf2 signaling. | Prostaglandins Other Lipid Mediat | 2024 | 38460759 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10643/papers?page=19